Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Nociception Level Index After Brachial Plexus Block In Upper Extremity Surgery

26 de maio de 2026 atualizado por: Michael Grach, Carmel Medical Center

Nociception Level Index After Brachial Plexus Block In Upper Extremity Surgery: Prospective Comparison Trial

The present prospective within-subject observational study will evaluate whether unilateral brachial plexus block (BPB) induces measurable lateralized autonomic modulation, assesses using bilateral Nociception Level (NoL) monitoring during standardized intraoperative stimuli under general anesthesia. Regional anesthesia efficacy is traditionally assessed through sensory and motor examination. However, objective physiologic markers reflecting sympathetic modulation remain limited. Forty five adults undergoing upper extremity surgery with BPB and general anesthesia, bilateral NoL monitoring will be performed during local anesthetic injection, endotracheal intubation, and nasogastric tube placement. The primary aim to investigate whether the brachial plexus block induces unilateral modulation of post-operative nervous system activity, assessed by inter-limb differences in NoL values during predefined nociceptive stimuli under general anesthesia. The secondary aim to evaluate the correlation between postoperative metrics, postoperative pain intensity, and analgesic consumption. From a clinical perspective, bilateral autonomic monitoring may offer a novel adjunctive method for intraoperative confirmation of block activity, particularly in sedated or anesthetized patients where traditional sensory testing is not feasible. Furthermore, inter-limb autonomic gradients could represent a future research pathway for objective assessment of regional anesthesia effectiveness beyond subjective pain scores.

Visão geral do estudo

Status

Recrutamento

Descrição detalhada

The hypotheses is that brachial plexus block (BPB) would induce an ipsilateral reduction in SANS activity compared to the contralateral side. The study intervention involved the standard administration of the BPB, a low-risk perineural injection of local anesthetics, conducted under real-time ultrasound guidance and monitored using NoL score measurements on both hands concurrently during endotracheal intubation. An ultrasound-guided single-shot BPB will be performed using 10 mL of 0.5% bupivacaine (50 mg) in all patients. The study duration for each participant approximately 5 hours. All participants undergo induction of general anesthesia using a standardized regimen: midazolam 0.025 mg/kg and fentanyl 0.25 mcg/kg prior to BPB, followed by propofol 2.5 mg/kg, fentanyl 0.75-1 mcg/kg, and rocuronium 0.7 mg/kg. Subsequently, participants will be intubated (including nasogastric tube placement) and ventilated with maintenance inhalational anesthetics, supplemented by continuous intravenous administration of the short-acting opioid remifentanil at doses of 30-70 ng/kg/min, adjusted according to hemodynamic parameters. Block efficacy will be assessed using postoperative pain (visual analog scale (VAS)), analgesic consumption, intraoperative analgesic consumption, and NoL measurements in the non-operated hand. In instances of suboptimal or failed block, all patients in this study will be provided with a backup perioperative analgesic regimen involving continuous intravenous administration of short-acting opioids and remifentanil at doses of 30-70 ng/kg/min .Safety assessments• Pre-anesthetic evaluation and eligibility for general and regional anesthesia• Standard monitoring will be performed according to the American Society of Anesthesiologists (ASA) o Pulse oximetry o Non-invasive blood pressure repeated measurement so 5-lead ECGo End tidal CO2• The principal investigator will assess adverse and serious adverse events, including identification, follow-up, documentation, and reporting to the IRB. Statistical analysis Primary Endpoint: The statistical null hypothesis posited that there would be no spatial differences in the NoL score measurements following BPB. Conversely, hypothesized that patients undergoing upper extremity surgery would exhibit lower ipsilateral hand NoL scores than the contralateral hand during noxious stimulation after BBP. Secondary Endpoints: The null hypothesis proposed that there would be no correlation between the NoL score measurements post-BPB and postoperative pain levels. Alternative hypothesis that a correlation exists between the contralateral hand NoL scores and postoperative pain levels in patients undergoing upper extremity surgery after BPB. Sample Size Determination Sample size calculation based on the primary endpoint, defined as the paired difference in NoL values between the blocked (ipsilateral) and contralateral limbs during endotracheal intubation. Based on preliminary observations and previously reported NoL variability, it is assumed that an expected mean paired difference of approximately 7 units, with a standard deviation of paired differences of 8 units. Using a two-sided paired t-test with a significance level (alpha) of 0.05 and a statistical power of 80%, a minimum of 34 evaluable subjects will be required. To account for potential exclusions and incomplete data, 45 participants are planned for enrollment. Statistical analysis This study will employ a prospective within-subject comparison design. Continuous variables will be presented as mean ± standard deviation, and categorical variables presented as counts and percentages. A pragmatic sample size was chosen based on the feasibility of previous NoL studies using within-subject designs. The study aims to enroll 45 patients to allow paired comparisons between the blocked and contralateral limbs during predefined nociceptive stimuli. The primary analysis based on paired comparisons of within-subject differences in NoL values between the blocked (ipsilateral) and non-blocked (contralateral) hands for each predefined stimulus (brachial plexus block injection, endotracheal intubation, and nasogastric tube placement). NoL index measured by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch. The device manufactured by Medasense (Ramat Gan, Israel). The monitoring module model PMD-200. The device is indicated for assessing pain levels in unconscious patients. Paired t-tests were used for the comparisons. Secondary exploratory analyses will evaluate the correlations between aggregated intraoperative NoL exposure, expressed as the percentage of total monitoring time spent within predefined NoL ranges (lower than 10, 10-25, and higher than 25), and postoperative pain outcomes, including VAS scores and analgesic consumption. Pearson's correlation coefficients will be calculated for these analyses. All statistical tests two-sided, and a P value <0.05 will be considered statistically significant. Variables Independent variables: discrete variable• gender (male/female)• operated hand (left/right)continuous variables:• age (years)• weight (kg)• height (cm)• ASA score Dependent variables: discrete variables• VAS (1-10) continuous variables Anesthesia induction times (HH:MM)• Patient entering the room • Performing BPB • Performing intubation post operative• Nasogastric tube• Induction completed• Surgery and recovery times (HH:MM)• Surgery start• Surgery end• Transfer to Post Anesthetic Care Unit (PACU)• Discharge from PACU• NoL levels difference between right- and left-hands during anesthesia induction• Peak levels differences (NoL index values)• After BPB• After intubation• After nasogastric tube placement• Time of peak levels differences (seconds)• After BPB• After intubation• After nasogastric tube placement• Left-right difference between duration of NoL index higher than 25 (seconds)• NoL levels in non-operated hand from patient entering the operating room to discharge from the PACU (NoL index values temporal variations)• Total time of NoL index higher than 25 (min)• Total time of NoL index between 10-25 (min)• Total time of NoL index lower than 10 (min)• Analgetic treatment • Perioperative total Remifentanil consumption (mg)• Post operative Morphine consumption (mg)• Peri and post operative Non-Steroidal-Anti-Inflammatory Drugs (NSAIDs) consumption• Paracetamol (g)• Ketorolac (mg)• Dipyrone (g)

Tipo de estudo

Observacional

Inscrição (Estimado)

45

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Michael Grach, DR.
  • Número de telefone: +972506265753
  • E-mail: Grachm@gmail.com

Estude backup de contato

Locais de estudo

      • Haifa, Israel, 3436212
        • Recrutamento
        • Carmel Medical Center
        • Contato:
        • Contato:
        • Investigador principal:
          • Michael Grach, Dr.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Método de amostragem

Amostra de Probabilidade

População do estudo

forty five patients over 18 years old meeting inclusion criteria

Descrição

Inclusion Criteria:

  • Age >18
  • Upper extremity surgery
  • Provision of signed and dated informed consent forms

Exclusion Criteria:

  • Pregnant women
  • Known allergic reaction to bupivacaine or other anesthetic medicine: Midazolam, Fentanyl, Propofol, Rocuronium, Remifentanil, Sevoflurane)
  • Known coagulopathy resulting in bleeding tendency
  • Thrombocytopenia
  • Abnormal laboratory coagulation tests in the previous week = Anticoagulation therapy Participation in other study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
patient both arms: one operated under brachial plexus block, other serves only as control;

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Comparison ipsilateral and contralateral NoL values in both arms
Prazo: five hours
Perioperative NoL score every 5 seconds (physiological parameter measurements, range 0-100) on both arms concurrently, begin before anesthesia induction, till patient will be discharged from PACU, by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch. The device monitoring module model PMD-200 manufactured by Medasense (Ramat Gan, Israel).
five hours

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Perioperative pain Assessments and correlations between NoL and VAS values
Prazo: five hours
Perioperative pain outcomes, VAS scores by questionnaires, range 1-10 at 3 time points: preoperative, post brachial plexus block and discharge from PACU. Correlations between VAS and NoL physiological parameter measurements, range 0-100, by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch at parallel time points. Monitoring module model PMD-200 the device manufactured by Medasense (Ramat Gan, Israel).
five hours
Perioperative correlations between total analgesic consumption with VAS and with NoL values
Prazo: Five hours

Perioperative correlations between total analgesic consumption with VAS and with NoL values:

  • Remifentanil (mg)
  • Morphine (mg) Non-Steroidal-Anti-Inflammatory Drugs (NSAIDs)
  • Paracetamol (g)
  • Ketorolac (mg)
  • Dipyrone (g)
Five hours

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de março de 2023

Conclusão Primária (Estimado)

30 de setembro de 2026

Conclusão do estudo (Estimado)

30 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

10 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de maio de 2026

Primeira postagem (Real)

2 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de maio de 2026

Última verificação

1 de março de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 0110-22-CMC

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

Afer completion of study and publication, data may be concidered to be shared

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever